Quarterly ResultMay 12, 2026, 05:07 PM
Dr. Reddy's Q4 Revenue ₹75.16B, Profit ₹2.2B; Recommends INR 8 Dividend
AI Summary
Dr. Reddy's Laboratories reported a significant decline in Q4FY26 consolidated revenue and profit after tax, with revenue down 11.6% YoY to ₹75,162 Mn and profit down 86% YoY to ₹2,201 Mn. Full-year FY26 profit after tax also decreased by 24.3% to ₹42,850 Mn, impacted by one-off items like lenalidomide shelf stock adjustment and asset impairments. The Board recommended a final dividend of INR 8 per equity share and approved key governance changes, including the re-appointment of Dr. K P Krishnan and the appointment of Mr. Srikanth Velamakanni as Independent Directors, and the appointment of Deloitte Haskins & Sells LLP as Statutory Auditors.
Key Highlights
- Q4FY26 consolidated revenue decreased 11.6% YoY to ₹75,162 Mn.
- Q4FY26 consolidated profit after tax attributable to equity holders decreased 86% YoY to ₹2,201 Mn.
- FY26 consolidated profit after tax attributable to equity holders decreased 24.3% YoY to ₹42,850 Mn.
- Board recommended a final dividend of INR 8 per equity share for FY26.
- North America Q4FY26 revenue decreased 51% YoY to ₹17,562 Mn, impacted by lenalidomide SSA.
- Deloitte Haskins & Sells LLP appointed as Statutory Auditors for five years.
- Dr. K P Krishnan re-appointed and Mr. Srikanth Velamakanni appointed as Independent Directors.